Cargando…

Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation

OBJECTIVES: To assess the effect of golimumab, with or without methotrexate (MTX), on serum lipids and inflammatory markers of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA) in two phase 3, randomised, placebo-controlled trials (GO-BEFORE and GO-FORWARD). METHODS: Patients i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kirkham, Bruce W, Wasko, Mary Chester, Hsia, Elizabeth C, Fleischmann, Roy M, Genovese, Mark C, Matteson, Eric L, Liu, Hongjuan, Rahman, Mahboob U
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888596/ https://www.ncbi.nlm.nih.gov/pubmed/23300117 http://dx.doi.org/10.1136/annrheumdis-2012-202089

Ejemplares similares

Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
por: Keystone, E C, et al.
Publicado: (2008)

Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial
por: Conaghan, Philip G, et al.
Publicado: (2011)

Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study
por: Smolen, Josef S, et al.
Publicado: (2014)

Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160
por: Smolen, Josef S, et al.
Publicado: (2012)

Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years
por: Rahman, Mahboob U, et al.
Publicado: (2011)

Golimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
por: Kay, Jonathan, et al.
Publicado: (2010)

Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
por: Kay, Jonathan, et al.
Publicado: (2015)

Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2011)

Golimumab in adolescents with Crohn's disease refractory to previous tumour necrosis factor antibody
por: Pichler, Judith, et al.
Publicado: (2020)

Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study
por: Visvanathan, Sudha, et al.
Publicado: (2010)

Golimumab: A Novel Anti-Tumor Necrosis Factor
por: Rossini, Maurizio, et al.
Publicado: (2013)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
por: Wagner, Carrie, et al.
Publicado: (2011)

Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study
por: Smolen, Josef S, et al.
Publicado: (2015)

Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort
por: Fisher, Anat, et al.
Publicado: (2014)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
por: Tanaka, Yoshiya, et al.
Publicado: (2011)

Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis
por: Wijbrandts, C A, et al.
Publicado: (2008)

Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study
por: Combe, Bernard, et al.
Publicado: (2014)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
por: Braun, Jürgen, et al.
Publicado: (2011)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
por: Braun, Jürgen, et al.
Publicado: (2011)

Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab
por: Wagner, Carrie L, et al.
Publicado: (2013)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
por: Deodhar, Atul, et al.
Publicado: (2015)

Paradoxical Reaction to Golimumab: Tumor Necrosis Factor α Inhibitor Inducing Psoriasis Pustulosa
por: Soto Lopes, Marien Siqueira, et al.
Publicado: (2013)

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
por: Huizinga, Tom W J, et al.
Publicado: (2014)

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
por: Schiff, M, et al.
Publicado: (2009)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
por: Braun, Jürgen, et al.
Publicado: (2014)

Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study
por: Song, Yeo-Jin, et al.
Publicado: (2022)

Golimumab for Rheumatoid Arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019)

Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers
por: Delcoigne, Benedicte, et al.
Publicado: (2023)

Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial
por: Brunner, Hermine I, et al.
Publicado: (2018)

Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort
por: Lamb, Maxine JE, et al.
Publicado: (2021)

Descriptive epidemiology of ependymal tumours in the United States
por: Villano, J L, et al.
Publicado: (2013)

Golimumab in unresponsive ulcerative colitis
por: Lippert, Elisabeth, et al.
Publicado: (2014)

Golimumab for the treatment of ulcerative colitis
por: Löwenberg, Mark, et al.
Publicado: (2014)

Golimumab in the treatment of ulcerative colitis
por: Cunningham, Georgina, et al.
Publicado: (2019)

Golimumab for the treatment of ulcerative colitis
por: Flamant, Mathurin, et al.
Publicado: (2017)

Efficacy and Safety of Subcutaneous Golimumab in Methotrexate‐Naive Patients With Rheumatoid Arthritis: Five‐Year Results of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2016)

Which lipid measurement should we monitor? An analysis of the LIPID study
por: Glasziou, Paul P, et al.
Publicado: (2014)

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lre8i9qnshb0ga99j3bqihuqem